Meet Some of the Physicians
and Cervical Spinal Cord
Injury Patients in the
AST-OPC1 Clinical Trial

Intellectual Property

Asterias maintains an extensive global intellectual property portfolio including broad issued claims to fundamental platform technologies including, but not limited to, scalable growth of pluripotent stem cells, methods of production and compositions of matter for several hESC-derived therapeutic cell types, and cellular immunotherapy using the telomerase antigen. Our patent portfolio includes patents and applications acquired from Geron Corporation, a pioneer in the fields of pluripotent stem cells and telomerase biology and new filings on work performed at Asterias. Our patent portfolio encompasses not just the traditional pharmaceutical markets of North America, Europe, and Japan, but also smaller or up-and-coming markets such as Australia, China, India, Singapore and Korea. Additional protection for our programs comes from the extensive know how our team has gathered from many years working on these programs, as well as the market protections in place in many countries for new biologic therapies and drugs for orphan conditions.
Asterias Biotherapeutics Tel: (510) 456-3800